ArticleAmerican heart journal plus : cardiology research and practice2026
FIB-4 index predicts short-term mortality in Vietnamese acute heart failure patients.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FIB-4 Index as a Non-Invasive Biomarker of Congestion and Prognosis in Heart Failure.Journal of clinical medicine · 2026Review
- Hypochloraemia independently associates with short-term mortality in patients with acute heart failure: a study from Vietnam.Open heart · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute heart failure (AHF) has high early mortality. The FIB-4 index indicates hepatic dysfunction in AHF, but its predictive power for short-term outcomes in developing countries is not well established. Methods: We conducted a prospective cohort study at Can Tho Central General Hospital, Vietnam, from May to December 2024 including adults aged ≥18, hospitalized with AHF and NT-proBNP levels ≥300 pg/mL. Exclusions were for those who died before blood sample collection, transferred, declined consent, or had chronic liver disease, active cancer, or end-stage renal disease. Survivors were followed up via phone for 30 days post-discharge. The primary endpoint was 30-day all-cause mortality. Results: The final analysis included 413 patients (mean age 70, 47.7% male). In-hospital mortality was 5.1% and did not associate to FIB-4. At 30 days post-discharge, 42(17%) of 247 patients with follow-up data died (37.3% loss to follow-up). Non-survivors had higher FIB-4 scores than survivors (3.3 vs. 2.3, Conclusion: In this exploratory single-center study of patients with AHF, FIB-4 demonstrated an independent association with 30-day mortality, with a threshold of 3.1 identifying high-risk individuals. These findings are hypothesis-generating, and external validation is warranted before FIB-4 can be recommended for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.